Elicio Therapeutics, Inc. (ELTX): Nasdaq/NYSE listing notice — Angion Biomedica gets Nasdaq bid-price deficiency notice; 180 days to cure

Elicio Therapeutics, Inc.

Received Nasdaq notice on Dec 15, 2022 for common stock closing below $1.00 for 30 consecutive business days.
Has until June 13, 2023 to regain compliance with minimum $1.00 closing bid for at least 10 consecutive days.
Company says notification will not adversely impact its ongoing strategic realignment process.
If not compliant by deadline, may qualify for an additional 180-day period and consider a reverse stock split.
Currently meets all other Nasdaq listing standards except the bid price requirement.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Elicio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

December 15, 2022, Angion Biomedica Corp. received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listing of Angion ’s common stock on Nasdaq and Angion does not believe the notification will adversely impact its ongoing strategic realignment process, previous

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-22-000073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.